Practice Note: How Bio-Rad’s old FCPA settlement became a ‘risk factor’
You would expect investors to be pleased and optimistic when their company resolves an FCPA case by paying relatively moderate penalties and landing a DOJ non-prosecution agreement, but one company thinks investors should also be concerned.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.